This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Doxorubicin Concentrate
  • /
  • A Randomized, Double-blind, Placebo-controlled Pha...
Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly

Read time: 2 mins
Last updated:2nd Sep 2013
Identifier: NCT01855750
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL).
Category Value
Date last updated at source 2017-06-01
Study type(s) Interventional
Expected enrolment 841
Study start date 2013-09-03
Estimated primary completion date 2018-06-18

View full details